TerSera Therap 
Welcome,         Profile    Billing    Logout  
 3 Products   0 Diseases  3 Products   1 Trial   250 News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Margenza (margetuximab-cmkb) / TerSera Therap
2019-004699-21: Study of Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in HER2-Positive Gastric or Gastroesophageal Junction Cancer

Not yet recruiting
2/3
860
Europe, RoW
Margetuximab, INCMGA00012, MGD013, Trastuzumab, MGAH22, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Herceptin
MacroGenics, Inc., MACROGENICS, INC., MacroGenics, Inc., Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator),  Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator), Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator)
Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer, Gastric Cancer or Gastroesophageal Junction Cancer, Diseases [C] - Cancer [C04]
 
 
MAHOGANY, NCT04082364 / 2019-004699-21: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Checkmark Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Sep 2021 - Sep 2021: Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Checkmark Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Sep 2021 - Sep 2021: Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Hourglass Sep 2020 - Mar 2021 : Completion of enrollment of module A of MAHOGANY trial
More
Active, not recruiting
2/3
82
Europe, US, RoW
margetuximab, MGAH22, Margenza®, Retifanlimab, MGA012, INCMGA00012, Tebotelimab, MGD013, Trastuzumab, Herceptin, Chemotherapy
MacroGenics, Zai Lab (Shanghai) Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
01/24
06/25
NCT04262804: A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Active, not recruiting
2
123
RoW
Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine), Chosen Chemotherapy (Vinorelbine ), Chosen Chemotherapy (Gemcitabine )
Zai Lab (Shanghai) Co., Ltd.
Breast Cancer Metastatic
09/21
12/23
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
09/24
07/27
NCT03219268: A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Checkmark Data from trial for DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for DLBCL at ASH 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Nov 2020 - Nov 2020: Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at ASCO 2020
More
Completed
1
277
Europe, US, RoW
tebotelimab 1 mg, MGD013, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab, MGAH22, Margenza
MacroGenics
Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer
02/23
02/23
Xermelo (telotristat etiprate) / Lexicon Pharma, TerSera Therap
NCT04810091: Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

Active, not recruiting
3
79
US
Placebo Administration, Questionnaire Administration, Telotristat Ethyl
M.D. Anderson Cancer Center, TerSera Therapeutics LLC
Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
08/25
08/25
NCT04543955: Telotristat With Lutathera in Neuroendocrine Tumors

Terminated
2
1
US
Telotristat (Low-Dose), Xermelo, Telotristat (High-Dose)
Lowell Anthony, MD, TerSera Therapeutics LLC
Neuroendocrine Tumors
06/22
06/22
NCT03453489: AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

Recruiting
2
6
US
Carbon C 11 Alpha-methyltryptophan, 11C-alpha-methyltryptophan, 11C-AMT, [11C] AMT, alpha-[11C]methyl-L-tryptophan, Laboratory Biomarker Analysis, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Telotristat Etiprate, LX1032 Hippurate, LX1606, LX1606 Hippurate, TPH Inhibitor LX1606, Tryptophan Hydroxylase Inhibitor LX1032, Tryptophan Hydroxylase Inhibitor LX1606
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
10/23
10/23
NCT03910387: Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Active, not recruiting
2
22
US
Gemcitabine, Gemzar, dFdCyd, Difluorodeoxycytidine, Nab-paclitaxel, ABI-007, Abraxane, Nanoparticle Albumin-bound Paclitaxel, Telotristat Ethyl, Xermelo
Emory University, National Cancer Institute (NCI), Lexicon Pharmaceuticals
Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
10/23
10/24
Varubi (rolapitant oral) / TerSera Therap, GSK
No trials found
Varubi IV (rolapitant IV) / TerSera Therap, GSK
No trials found
Quzyttir (cetirizine injection) / TerSera Therap
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Margenza (margetuximab-cmkb) / TerSera Therap
2019-004699-21: Study of Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in HER2-Positive Gastric or Gastroesophageal Junction Cancer

Not yet recruiting
2/3
860
Europe, RoW
Margetuximab, INCMGA00012, MGD013, Trastuzumab, MGAH22, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Herceptin
MacroGenics, Inc., MACROGENICS, INC., MacroGenics, Inc., Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator),  Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator), Zai Lab (Shanghai) Co., Ltd. (MacroGenics collaborator)
Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer, Gastric Cancer or Gastroesophageal Junction Cancer, Diseases [C] - Cancer [C04]
 
 
MAHOGANY, NCT04082364 / 2019-004699-21: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Checkmark Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Sep 2021 - Sep 2021: Interim data from cohort A part 1 of MAHOGANY trial in combination with retifanlimab for advanced HER2+ gastric cancer at ESMO 2021
Checkmark Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Sep 2021 - Sep 2021: Safety and efficacy data from cohort A of MAHOGANY trial in combination with INCMGA00012 for gastroesophageal junction cancerat ESMO 2021
Hourglass Sep 2020 - Mar 2021 : Completion of enrollment of module A of MAHOGANY trial
More
Active, not recruiting
2/3
82
Europe, US, RoW
margetuximab, MGAH22, Margenza®, Retifanlimab, MGA012, INCMGA00012, Tebotelimab, MGD013, Trastuzumab, Herceptin, Chemotherapy
MacroGenics, Zai Lab (Shanghai) Co., Ltd.
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer
01/24
06/25
NCT04262804: A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Active, not recruiting
2
123
RoW
Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine), Chosen Chemotherapy (Vinorelbine ), Chosen Chemotherapy (Gemcitabine )
Zai Lab (Shanghai) Co., Ltd.
Breast Cancer Metastatic
09/21
12/23
MARGOT, NCT04425018: MARGetuximab Or Trastuzumab

Active, not recruiting
2
174
US
Paclitaxel, Taxol, Onxal, Pertuzumab, Perjeta, Margetuximab, Margenza, Trastuzumab, Herceptin, Kanjinti, Ogivri, Herzuma
Dana-Farber Cancer Institute, MacroGenics, Translational Breast Cancer Research Consortium
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
09/24
07/27
NCT03219268: A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Checkmark Data from trial for DLBCL at ASH 2020
Dec 2020 - Dec 2020: Data from trial for DLBCL at ASH 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Nov 2020 - Nov 2020: Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at SITC 2020
Checkmark Data from trial in combination with Margetuximab for patients with unresectable or metastatic neoplasms at ASCO 2020
More
Completed
1
277
Europe, US, RoW
tebotelimab 1 mg, MGD013, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab, MGAH22, Margenza
MacroGenics
Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer
02/23
02/23
Xermelo (telotristat etiprate) / Lexicon Pharma, TerSera Therap
NCT04810091: Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

Active, not recruiting
3
79
US
Placebo Administration, Questionnaire Administration, Telotristat Ethyl
M.D. Anderson Cancer Center, TerSera Therapeutics LLC
Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm
08/25
08/25
NCT04543955: Telotristat With Lutathera in Neuroendocrine Tumors

Terminated
2
1
US
Telotristat (Low-Dose), Xermelo, Telotristat (High-Dose)
Lowell Anthony, MD, TerSera Therapeutics LLC
Neuroendocrine Tumors
06/22
06/22
NCT03453489: AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

Recruiting
2
6
US
Carbon C 11 Alpha-methyltryptophan, 11C-alpha-methyltryptophan, 11C-AMT, [11C] AMT, alpha-[11C]methyl-L-tryptophan, Laboratory Biomarker Analysis, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Telotristat Etiprate, LX1032 Hippurate, LX1606, LX1606 Hippurate, TPH Inhibitor LX1606, Tryptophan Hydroxylase Inhibitor LX1032, Tryptophan Hydroxylase Inhibitor LX1606
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Carcinoid Syndrome, Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
10/23
10/23
NCT03910387: Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

Active, not recruiting
2
22
US
Gemcitabine, Gemzar, dFdCyd, Difluorodeoxycytidine, Nab-paclitaxel, ABI-007, Abraxane, Nanoparticle Albumin-bound Paclitaxel, Telotristat Ethyl, Xermelo
Emory University, National Cancer Institute (NCI), Lexicon Pharmaceuticals
Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
10/23
10/24
Varubi (rolapitant oral) / TerSera Therap, GSK
No trials found
Varubi IV (rolapitant IV) / TerSera Therap, GSK
No trials found
Quzyttir (cetirizine injection) / TerSera Therap
No trials found

Download Options